¥ 4653
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Solid dividends
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value
Target Price
The average target price of 4523.T is 5135 and suggests 10% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
